Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
This article evaluates the safety and tolerability of tolterodine for the treatment of overactive bladder (OAB), which is defined as urinary urgency with or without urgency incontinence, usually with frequency and nocturia, but without infection or pathology. OAB affects tens of millions of people worldwide. Data are summarized from clinical trials and from postmarketing surveillance studies.
Roberts
Richard G
RG
Department of Family Medicine, University of Wisconsin Medical School, Madison, USA.
Garely
Alan D
AD
Bavendam
Tamara
T
D000328:Adult; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003408:Cresols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068737:Tolterodine Tartrate; D014549:Urinary Incontinence / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate